Is sirolimus a targeted drug?

Sirolimus (sirolimus) is a well-known allosteric and PPI-targeting drug that affects the mTOR (mammalian target of rapamycin) signaling pathway. Sirolimus is a macrolide antibiotic with immunosuppressive properties that inhibits a protein, target of rapamycin (TOR), a key regulatory kinase that controls cytokine-mediated cell proliferation. The potential role of sirolimus in renal transplantation has been demonstrated.

Use sirolimus in regimens that avoid the use of calcineurin inhibitors or corticosteroids of interest. In addition, for complications caused by other drugs, sirolimus can be used instead. Interactions between sirolimus and calcineurin inhibitors, especially cyclosporine, must be carefully monitored. As with many other immunosuppressants, there is evidence that sirolimus is metabolized more rapidly in children compared with adults. Experience with the use of sirolimus is limited and the drug should be used with caution given the possible long-term risks.

SirolimusThe original drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of each box of 1mg*10 tablets is about 400 yuan. The domestic drug is only available to patients with anti-rejection reactions in organ transplantation. Patients who do not meet the conditions may not be able to purchase this drug. The original sirolimus drug has also been launched overseas. The price of the Turkish version of Specifications1mg*100 tablets per box is around RMB 2,000 (the price may fluctuate due to exchange rates). The ingredients of the original drugs marketed in China are basically the same as those of foreign original drugs. Currently, there are no generic sirolimus drugs produced in other countries.